The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension
Open accessAbstract
BACKGROUND: Recently, a cluster of patients was observed in France in whom primary pulmonary hypertension developed in patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents), which are used for weight control. We investigated the potential role of anorexic agents and other suspected risk factors for primary pulmonary hypertension. METHODS: In a case-control study, we assessed 95 patients with primary pulmonary hypertension from 35 centers in France, Belgium, the United Kingdom, and the Netherlands and 355 controls recruited from general practices and matched to the patients' sex and age. RESULTS: The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6.3; 95 percent confidence interval, 3.0 to 13.2). For the use of anorexic agents in the preceding year, the odds ratio was 10.1 (95 percent confidence interval, 3.4 to 29.9). When anorexic drugs were used to a total of more than three months, the odds ratio was 23.1 (95 percent confidence interval, 6.9 to 77.7). We also confirmed an association with several previously identified risk factors: a family history of pulmonary hypertension, infection with the human immunodeficiency virus, cirrhosis, and use of cocaine or intravenous drugs. CONCLUSIONS: The use of anorexic drugs was associated with the development of primary pulmonary hypertension. Active surveillance for this disease should be considered, particularly since their use is expected to increase in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary Pulmonary Hypertension
Rich, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., Detre, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, S. K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-216 · Cited by 2,027
Self-citationThe Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,558
Self-citationTreatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)
Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J., & Long, W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-7-485 · Cited by 701
Increased plasma serotonin in primary pulmonary hypertension
Hervé, P., Launay, J., Scrobohaci, M.-L., Brenot, F., Simonneau, G., PETITPRETZ, P., Poubeau, P., Cerrina, J., Duroux, P., & Drouet, L. O. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80156-9 · Cited by 557
Self-citationHadengue, A., Benhayoun, M. K., Lebrec, D., & Benhamou, J. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90225-a · Cited by 497
Primary Pulmonary Hypertension and Cirrhosis: Are They Related?
McDonnell, P. J., Toye, P. A., & Hutchins, G. M. (1983) · American Review of Respiratory Disease · doi:10.1164/arrd.1983.127.4.437 · Cited by 318
Primary Pulmonary Hypertension
Rubin, L. J. (1993) · CHEST Journal · doi:10.1378/chest.104.1.236 · Cited by 308
Primary pulmonary hypertension and fenfluramine use.
Brénot, F., Hervé, P., PETITPRETZ, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 247
Self-citationPETITPRETZ, P., Brénot, F., Azarian, R., Parent, F., Rain, B., Hervé, P., & Simonneau, G. (1994) · Circulation · doi:10.1161/01.cir.89.6.2722 · Cited by 238
Self-citationPulmonary hypertension and fenfluramine
Douglas, J. G., Munro, J., KITCHIN, A. H., Muir, A. L., & Proudfoot, A. T. (1981) · BMJ · doi:10.1136/bmj.283.6296.881 · Cited by 180
Research works printed but not linked: 3
- Gurtner HP, 1985, Cor Vasa, 27, 160
- Michelakis ED, 1995, Am J Respir Crit Care Med, 151, A725
- Russel LA, 1992, Am Rev Respir Dis, 145, A717
Cited by
Sorted by citations
Items 701–800 of 999
Focus on Primary Care Evaluation, Management, and Treatment of Obesity in Women
Dickerson, V. M. (2001) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200110000-00024 · Cited by 9
Montastruc, J., Bagheri, H., Lacroix, I., Olivier, P., Durrieu, G., Damase-Michel, & Lapeyre‐Mestre, M. (2005) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)33561-7 · Cited by 9
Malysz, J., Farrugia, G., Ou, Y., Szurszewski, J. H., Nehra, A. X., & Gibbons, S. J. (2002) · Journal of Andrology · doi:10.1002/j.1939-4640.2002.tb02348.x · Cited by 9
Pharmacological Promiscuity and Molecular Properties
Peters, J. (2012) · doi:10.1002/9781118098141.ch3 · Cited by 9
Conflicts of Interest — Editorialists Respond
Manson, J. E., & Faich, G. A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351414 · Cited by 9
How to manage primary pulmonary hypertension
Ricciardi, M. J., & Rubenfire, M. (1999) · Postgraduate Medicine · doi:10.3810/pgm.1999.03.596 · Cited by 9
Letter to the Editor ofBiometrics
Greenland, S., Lin, D. Y., Kronmal, R. A., & Psaty, B. M. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00990.x · Cited by 9
Diagnosing Heart Failure with Preserved Ejection Fraction in Obese Patients
Basha, M., Stavropoulou, E., Nikolaidou, A., Dividis, G., Peteinidou, E., Tsioufis, P., Kamperidis, N., Dimitriadis, K. S., Karamitsos, T. D., Giannakoulas, G. A., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061980 · Cited by 9
Humbert, M. J. C., Simonneau, G., & Dinh‐Xuan, A. T. (2011) · European Respiratory Journal · doi:10.1183/09031936.00075211 · Cited by 8
Self-citationRajamani, S., Studenik, C. R., Lemmens‐Gruber, R., & Heistracher, P. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703118 · Cited by 8
Crotalaria (Monocrotaline) Pulmonary Hypertension
Kay, J. M. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.06.013 · Cited by 8
Turpin, M. A. C., Hebert, V. Y., Chotibut, T., Wensler, H., Krentzel, D., Varner, K. J., Burn, B. R., Chen, Y., Abreo, F. W., & Dugas, T. R. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv126 · Cited by 8
Anesthesia Risks in Patients Who Have Had Antiobesity Medication
Shiffman, M. A. (1998) · The American Journal of Cosmetic Surgery · doi:10.1177/074880689801500102 · Cited by 8
Dravet syndrome—toward an optimal and disease-specific treatment
Schoonjans, A., & Ceulemans, B. (2021) · Clinical Epileptology · doi:10.1007/s10309-021-00399-z · Cited by 9
Clinical Investigations of Antiobesity Drugs
Wilding, J. P. H. (2007) · Elsevier eBooks · doi:10.1016/b978-012370633-1/50014-1 · Cited by 8
Pathobiology of pulmonary arterial hypertension.
Naeije, R., & Rondelet, B. (2004) · PubMed · Cited by 8
Obese Patients With Binge-Eating Disorder
Marcus, M. D., & Levine, M. D. (2005) · Humana Press eBooks · doi:10.1385/1-59259-865-x:143 · Cited by 8
Explorations fonctionnelles dans l’hypertension artérielle pulmonaire
Chaouat, A., Canuet, M., Kraemer, J. P., Enache, I., Ducoloné, A., Kessler, R., & Weitzenblum, E. (2005) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(05)85730-4 · Cited by 8
SEVERE PULMONARY HYPERTENSION: CRITICAL CARE CLINICS
McLaughlin, V. V., & Rich, S. (2001) · Critical Care Clinics · doi:10.1016/s0749-0704(05)70177-9 · Cited by 8
Self-citationRapid Clot Formation and Abnormal Fibrin Structure in a Symptomatic Patient Taking Fenfluramine
Carr, M. E., Carr, S. L., Martin, E. J., & Johnson, B. A. (2001) · Angiology · doi:10.1177/000331970105200511 · Cited by 8
Genetics of primary pulmonary hypertension
Morse, J. H., & Knowles, J. A. (2001) · Progress in Pediatric Cardiology · doi:10.1016/s1058-9813(01)00073-x · Cited by 8
Investigational drugs for eating disorders
Crow, S. J., & Brown, E. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.3.491 · Cited by 8
The treatment of obesity with drugs
Hirsch, J. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/67.1.2 · Cited by 8
Genetic studies of pulmonary arterial hypertension
Morse, J. H. (2003) · Lupus · doi:10.1191/0961203303lu359xx · Cited by 8
Cardiovascular effects of anti-obesity medications: the perils and promise
Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7
Morrell, N. W. (2020) · doi:10.1093/med/9780198746690.003.0374 · Cited by 7
Updated Hemodynamic Definition and Classification of Pulmonary Hypertension
Lechartier, B., Kularatne, M., Jaïs, X., Humbert, M. J. C., & Montani, D. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1770115 · Cited by 7
Barateau, L., Baillieul, S., Andréjak, C., Béquignon, É., Boutouyrie, P., Dauvilliers, Y. A., Gagnadoux, F., Geoffroy, P. A., Micoulaud‐Franchi, J., Montani, D., et al. (2023) · Médecine du Sommeil · doi:10.1016/j.msom.2023.06.001 · Cited by 7
Aminorex to Fen/Phen: An Epidemic Foretold
Pollick, C. (1999) · Circulation · doi:10.1161/01.cir.100.25.e147 · Cited by 7
Mélot, C., & Naeije, R. (2011) · Comprehensive physiology · doi:10.1002/j.2040-4603.2011.tb00333.x · Cited by 7
Grimaldi‐Bensouda, L., Rossignol, M., Danchin, N., Dallongeville, J., Bruckert, É., Banayan, J., Cottin, Y., Aubrun, E., Khachatryan, A., Bénichou, J., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.127 · Cited by 7
Self-citationKim, S.-S., Lee, H., & Lee, K. (2009) · Journal of Chromatography B · doi:10.1016/j.jchromb.2009.02.049 · Cited by 7
Managing obesity like any other chronic condition
Agrawal, M., Worzniak, M., & Diamond, L. M. (2000) · Postgraduate Medicine · doi:10.3810/pgm.2000.07.1158 · Cited by 7
Primary pulmonary hypertension: molecular basis and potential for therapy
Rudarakanchana, N., & Morrell, N. W. (2004) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399404007483 · Cited by 7
Ni, W., Fink, G. D., & Watts, S. W. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114017 · Cited by 7
Grünig, G., Baghdassarian, A., Park, S., Pylawka, S., Bleck, B., Reibman, J., Rosenzweig, E. B., & Durmuş, N. (2015) · Biomarker Insights · doi:10.4137/bmi.s29514 · Cited by 7
Pulmonary Complications of Abdominal Diseases
Rodriguez‐Roisin, R., & Huchon, G. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00093-2 · Cited by 7
Pulmonary Arterial Hypertension and Obesity†
Williams, W. H., Safford, R. E., Heckman, M. G., Crook, J. E., & Burger, C. D. (2010) · The Open Obesity Journal · doi:10.2174/1876823701002010132 · Cited by 7
Stimulants and Pulmonary Arterial Hypertension: An Update
Ramírez, R. L., Pérez, V. D. J., & Zamanian, R. T. (2018) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-17.2.49 · Cited by 7
Castelain, V., Lavigne, T., Jaeger, A., & Schneider, F. (2005) · Réanimation · doi:10.1016/j.reaurg.2005.02.009 · Cited by 8
Dexfenfluramine-induced contraction of human and rat isolated pulmonary arteries
Patnaude, L. A., Undem, B. J., & O’Rourke, S. T. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00458-1 · Cited by 7
Respiratory toxicities from stimulant use
Albertson, T. E., & Walby, W. F. (1997) · Clinical Reviews in Allergy & Immunology · doi:10.1007/bf02737699 · Cited by 7
Relearning the Lessons of History
Langleben, D. (1998) · CHEST Journal · doi:10.1378/chest.114.1_supplement.55s · Cited by 7
Classificação e avaliação diagnóstica da hipertensão pulmonar
(2005) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132005000800002 · Cited by 7
Pulmonary Complications of Abdominal Disease
Rodriguez‐Roisin, R., & Barberà, J. A. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00083-3 · Cited by 6
Diagnostic et classification des hypertensions artérielles pulmonaires
Provencher, S., Martel, S., Jaïs, X., Sitbon, O., Humbert, M. J. C., & Simonneau, G. (2005) · La Presse Médicale · doi:10.1016/s0755-4982(05)84205-8 · Cited by 7
Self-citationIncreased release of serotonin from rat ileum due to dexfenfluramine
Rezaie-Majd, S., Murar, J., Nelson, D. P., Kelly, R. F., Hong, Z., Lang, I. M., Varghese, A., & Weir, Ε. K. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00191.2004 · Cited by 7
Pathology of pulmonary hypertension
Rabinovitch, M. (2001) · Progress in Pediatric Cardiology · doi:10.1016/s1058-9813(01)00071-6 · Cited by 7
Serotonin-Induced Inhibition of KVCurrent
Varghese, A., Hong, Z., & Weir, E. K. (2006) · Circulation Research · doi:10.1161/01.res.0000219683.65556.74 · Cited by 7
Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension. A New Chapter of the Story
Simonneau, G., & Humbert, M. J. C. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201709-1962ed · Cited by 7
Self-citationOverlapping pulmonary hypertension phenotypes in smokers: a call to action
Syed, M., Humbert, M. J. C., Kovacs, G., & Sahay, S. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00259-0 · Cited by 6
Advances in the discovery of drugs that treat pulmonary arterial hypertension
Zolty, R. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2192919 · Cited by 7
Pharmacovigilance: A Necessary Tool for Drug Safety Monitoring Globally
Mansuri, A., & Zaman, T. U. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i4.6516 · Cited by 8
Pulmonary Arterial Hypertension and Benfluorex: 5 Case Reports
Bondon‐Guitton, E., Prévôt, G., Didier, A. P., & Montastruc, J. (2011) · Therapies · doi:10.2515/therapie/2011018 · Cited by 6
Gender issues in pulmonary vascular disease
Robles, A. M., & Shure, D. (2004) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2004.01.007 · Cited by 6
Mazindol: a risk factor for pulmonary arterial hypertension?
Konofal, É., Benzouid, C., Delclaux, C., Lecendreux, M., & Hussey, E. K. (2017) · Sleep Medicine · doi:10.1016/j.sleep.2017.02.020 · Cited by 6
Iranian Pulmonary Arterial Hypertension Registry.
Masjedi, M. R., Fahimi, F., Sharif-Kashani, B., Mohammad, M. M., Saliminejad, L., & Monjazebi, F. (2015) · PubMed Central · Cited by 6
Fenfluramine: Back From the Dead
Wurtman, R. J., & Wurtman, J. J. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.07.009 · Cited by 6
Lessons in women's health: body image and pulmonary disease.
Day, A. (1998) · Europe PMC (PubMed Central) · Cited by 6
Clinical Presentation, Differential Diagnosis, and Vasodilator Testing of Pulmonary Hypertension
Edelman, J. D. (2007) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253207301355 · Cited by 6
Operation for anorexigen-associated valvular heart disease
Caccitolo, J. A., Connolly, H. M., Rubenson, D. S., Orszulak, T. A., & Schaff, H. V. (2001) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2001.116315 · Cited by 6
Diagnosis and assessment of pulmonary hypertension in infants and children
Barst, R. J. (2001) · Progress in Pediatric Cardiology · doi:10.1016/s1058-9813(01)00074-1 · Cited by 6
Hipertensão pulmonar: relato de seis casos e atualização do tema
Barreto, S. S. M., & Gazzana, M. B. (2000) · Jornal de Pneumologia · doi:10.1590/s0102-35862000000600009 · Cited by 6
The need for greater involvement of regulatory agencies in assessing adverse drug reactions.
Sniderman, A. D. (2000) · Europe PMC (PubMed Central) · Cited by 6
Current Management of Pulmonary Hypertension
Dincer, H. E., & Presberg, K. W. (2004) · Clinical Pulmonary Medicine · doi:10.1097/01.cpm.0000107641.66465.1e · Cited by 6
Hypertension artérielle pulmonaire : de la génétique aux traitements
Humbert, M. J. C., Yaici, A., Sztrymf, B., & Montani, D. (2004) · Revue de Pneumologie Clinique · doi:10.1016/s0761-8417(04)72099-4 · Cited by 6
Pregnancy and Pulmonary Hypertension
Parambil, J. G., & McGoon, M. D. (2007) · doi:10.1002/9780470994955.ch6 · Cited by 6
RE: Pulmonary Hypertension Associated with Use of Phentermine?
Hendricks, E. J., & Rothman, R. B. (2011) · Yonsei Medical Journal · doi:10.3349/ymj.2011.52.5.869 · Cited by 6
Does phentermine inhibit monoamine oxidase?
Rothman, R. B. (1999) · The Lancet · doi:10.1016/s0140-6736(05)74358-0 · Cited by 6
Gatzoulis, M. Α., Swan, L., Therrien, J., & Pantely, G. A. (2005) · doi:10.1002/9780470750544.ch22 · Cited by 6
From Symptomatic Therapies to Disease-Modifying Approaches for Neuronal Sodium Channel Disorders
Dinoi, G., Canfora, I., D’Agnano, D., Boccanegra, B., Conte, E., Luca, A. D., Liantonio, A., Sciruicchio, V., & Imbrici, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010032 · Cited by 6
Becerra‐Muñoz, V. M., Gómez, J.-T., & Subías, P. E. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2023.12.010 · Cited by 5
Xu, Y., Chen, D., & Liu, L. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1371704 · Cited by 5
A history of pharmacoepidemiology
Bégaud, B. (2018) · Therapies · doi:10.1016/j.therap.2018.10.003 · Cited by 5
Self-citationDetection and Evaluation of Drug-associated Pulmonary Arterial Hypertension
Jambon-Barbara, C., Hlavaty, A., Grynblat, J., Antigny, F., Chaumais, M., Humbert, M. J. C., Cracowski, J., Montani, D., & Khouri, C. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202411-2339pp · Cited by 5
How can benfluorex-related heart valve disease be identified by echocardiography?
Tribouilloy, C. M., Ruşinaru, D., & Andréjak, M. (2011) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2011.07.001 · Cited by 5
Effect of Serotonin Reuptake Inhibitors on Pulmonary Hemodynamics in Humans
Pleym (2011) · Journal of Clinical Medicine Research · doi:10.4021/jocmr654w · Cited by 5
Pharmacotherapy for obesity: a field in crisis?
Fenske, W. K., Parker, J., & Bloom, S. R. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.50 · Cited by 5
Drug. Therapy for Obesity: An Update
Popovich, N. G., & WOOD, O. B. (1997) · Journal of the American Pharmaceutical Association (1996) · doi:10.1016/s1086-5802(16)30175-9 · Cited by 5
Drug-Induced Pulmonary Hypertension: The First 50 Years
Pérez, V. D. J. (2017) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-15.3.133 · Cited by 5
A New Classification of Pulmonary Hypertension
Rich, S. (2002) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-1.1.3 · Cited by 5
Self-citation[Pulmonary arterial hypertension].
Guiot, J., Parzibut, G., Weber, T., Davin, L., Dulgheru, R., Lancellotti, P., Louis, R. E., & Jl, V. (2019) · PubMed · Cited by 5
Churg, A., & Wright, J. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5770-3.00011-0 · Cited by 5
Pediatric strength training: benefits, concerns, and current trends
Wang, X., Dubrosa, F., O’Connor, M., Sangiuolo, K., & Milanaik, R. L. (2022) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001187 · Cited by 5
1 Central nervous system stimulants and drugs that suppress appetite
Sequeira, R. P. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29001-9 · Cited by 5
Qu’est-ce que la pharmacoépidémiologie?
Montastruc, J., Sommet, A., Montastruc, F., Moulis, G., Bagheri, H., Damase‐Michel, C., & Lapeyre‐Mestre, M. (2015) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30970-7 · Cited by 6
Pulmonary Arterial Hypertension and Therapeutic Interventions
Gabra, N. I., Mahmoud, O., Ishikawa, O., Shah, V., ALTSCHUL, E. L., Oron, M., & Mina, B. A. (2019) · International Journal of Angiology · doi:10.1055/s-0039-1692452 · Cited by 5
Evaluation of Cardiac Function
Nichols, K. J., Kronenberg, M. W., & Bokhari, S. (2004) · Springer eBooks · doi:10.1007/978-1-4612-2038-1_7 · Cited by 5
PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756
Abi‐Dargham, A., Simpson, N. R., Kegeles, L. S., Parsey, R. V., Hwang, D., Anjilvel, S., Zea‐Ponce, Y., Lombardo, I., Heertum, R. V., Mann, J. J., et al. (1999) · Synapse · doi:10.1002/(sici)1098-2396(199905)32:2 · Cited by 115
New Therapeutic Approaches to Non-Insulin-Dependent Diabetes Mellitus
Bloomgarden, Z. T. (1997) · Endocrine Practice · doi:10.4158/ep.3.5.307 · Cited by 5
Pulmonary Arterial Hypertension: An Overview
Klinger, J. R. (2007) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253207301447 · Cited by 5
Hypertension artérielle pulmonaire féminine
Sanchez, O., Marié, E., Lerolle, U., Wermert, D., Israël‐Biet, D., & Meyer, G. (2008) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(08)71585-7 · Cited by 5
Ethical Issues in Lung Transplantation
Lawrence, E. C. (1998) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40298-8 · Cited by 5
Hypertension artérielle pulmonaire
Montani, D., Sitbon, O., Fadel, É., Dartevelle, P., Nunès, H., Lebrec, D., Simonneau, G., & Humbert, M. J. C. (2004) · Encyclopédie médico-chirurgicale. Pneumologie · doi:10.1016/j.emcpn.2004.02.001 · Cited by 5
Self-citationRecent and Future Drugs for the Treatment of Obesity
Gaal, L. F. V., Mertens, I. L., & Leeuw, I. H. D. (2001) · doi:10.1002/0470846739.ch31 · Cited by 5
Obesity Pharmacotherapy from a Regulatory Perspective: Overview and Key Challenges
Hutchinson, N., & Ryder, S. W. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100169 · Cited by 5
Flegal, K. M. (2000) · Elsevier eBooks · doi:10.1016/b978-012288145-9/50075-9 · Cited by 5
Grynblat, J., Hlavaty, A., Savale, L., Weatherald, J. C., Bozec, A. L., Aguado, B., Chaumais, M., Humbert, M. J. C., Khouri, C., & Montani, D. (2025) · ERJ Open Research · doi:10.1183/23120541.00382-2025 · Cited by 4
Pathophysiology of Pulmonary Arterial Hypertension
Farber, H. W. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-075-5_4 · Cited by 3
Amphetamines in child medicine: a review of ClinicalTrials.gov
Alalalmeh, S. O., Hegazi, O. E., Shahwan, M., Alshehri, F., Ashour, A. M., Algarni, A. S., & Alorfi, N. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1280562 · Cited by 4
Metadata
- Authors
- Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., Simonneau, G., & Bégaud, B.
- Affiliations
- Jewish General Hospital (CA)
- Hôpital Antoine-Béclère (FR)
- University of Illinois Chicago (US)
- Centre Hospitalier Universitaire de Liège (BE)
- University of Sheffield (GB)
- Hammersmith Hospital (GB)
- Maastricht University Medical Centre (NL)
- Hôpital Bichat-Claude-Bernard (FR)
- Hôpital Pellegrin (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1996-08-29
- Volume
- 335
- Issue
- 9
- Pages
- 609-616
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2329065056
- Cited by
- 1,162
- References
- 26
- Citations by year
- 2026: 7 · 2025: 23 · 2024: 22 · 2023: 21 · 2022: 22 · 2021: 16 · 2020: 16 · 2019: 20 · 2018: 27 · 2017: 29 · 2016: 18 · 2015: 30 · 2014: 27 · 2013: 39 · 2012: 34
- FWCI
- 71.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- idiopathic pulmonary arterial hypertension, appetite suppressants, drug-induced pulmonary hypertension, risk factors, HIV infection, liver cirrhosis, cocaine use, intravenous drug use, weight management
- MeSH terms
- Adolescent, Adult, Aged, Appetite Depressants, Belgium, Female, Fenfluramine, France, United Kingdom, Heart Function Tests, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Netherlands, Prospective Studies, Respiratory Function Tests, Risk Factors, Incidence, Logistic Models, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
